241 related articles for article (PubMed ID: 32378877)
1. Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities.
Zhang J; Shen H; Xu J; Liu L; Tan J; Li M; Xu N; Luo S; Wang J; Yang F; Tang J; Li Q; Wang Y; Yu L; Yan Z
ACS Nano; 2020 May; 14(5):6305-6322. PubMed ID: 32378877
[TBL] [Abstract][Full Text] [Related]
2. pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis.
Jia Z; Gong Y; Pi Y; Liu X; Gao L; Kang L; Wang J; Yang F; Tang J; Lu W; Li Q; Zhang W; Yan Z; Yu L
Mol Pharm; 2018 Jan; 15(1):53-62. PubMed ID: 29148802
[TBL] [Abstract][Full Text] [Related]
3. Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis.
Zhou JE; Sun L; Liu L; Jia Y; Han Y; Shao J; Wang J; Wang Y; Yu L; Yan Z
J Control Release; 2022 Mar; 343():175-186. PubMed ID: 35092721
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells.
Ge WS; Wu JX; Fan JG; Wang YJ; Chen YW
World J Gastroenterol; 2011 Sep; 17(36):4090-8. PubMed ID: 22039322
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy.
Omar R; Yang J; Liu H; Davies NM; Gong Y
Rev Physiol Biochem Pharmacol; 2016; 172():1-37. PubMed ID: 27534415
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis.
Kao YH; Lin YC; Tsai MS; Sun CK; Yuan SS; Chang CY; Jawan B; Lee PH
Biochim Biophys Acta; 2014 Sep; 1842(9):1720-32. PubMed ID: 24970745
[TBL] [Abstract][Full Text] [Related]
7. Hyperbranched lipoid-based lipid nanoparticles for bidirectional regulation of collagen accumulation in liver fibrosis.
Qiao JB; Fan QQ; Zhang CL; Lee J; Byun J; Xing L; Gao XD; Oh YK; Jiang HL
J Control Release; 2020 May; 321():629-640. PubMed ID: 32135224
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of pirfenidone and siRNA in ZIF-based nanoparticles for dual inhibition of hepatic stellate cell activation in liver fibrotic therapy.
Wang K; Chen H; Qin S; Chen S; Zhang Q; Chen J; Di D; Su G; Yuan Y
Colloids Surf B Biointerfaces; 2023 Nov; 231():113567. PubMed ID: 37797465
[TBL] [Abstract][Full Text] [Related]
9. HMGB1-induced autophagy facilitates hepatic stellate cells activation: a new pathway in liver fibrosis.
Li J; Zeng C; Zheng B; Liu C; Tang M; Jiang Y; Chang Y; Song W; Wang Y; Yang C
Clin Sci (Lond); 2018 Aug; 132(15):1645-1667. PubMed ID: 29907694
[TBL] [Abstract][Full Text] [Related]
10. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
11. Remodeling liver microenvironment by L-arginine loaded hollow polydopamine nanoparticles for liver cirrhosis treatment.
Wang Y; Liu Y; Liu Y; Zhong J; Wang J; Sun L; Yu L; Wang Y; Li Q; Jin W; Yan Z
Biomaterials; 2023 Apr; 295():122028. PubMed ID: 36739734
[TBL] [Abstract][Full Text] [Related]
12. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z
J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139
[TBL] [Abstract][Full Text] [Related]
13. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
[TBL] [Abstract][Full Text] [Related]
14. The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells.
Li Q; Yan Z; Li F; Lu W; Wang J; Guo C
Nanotechnology; 2012 Jul; 23(26):265101. PubMed ID: 22700686
[TBL] [Abstract][Full Text] [Related]
15. Targeting CCl
Bangen JM; Hammerich L; Sonntag R; Baues M; Haas U; Lambertz D; Longerich T; Lammers T; Tacke F; Trautwein C; Liedtke C
Hepatology; 2017 Oct; 66(4):1242-1257. PubMed ID: 28520165
[TBL] [Abstract][Full Text] [Related]
16. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats.
Lang Q; Liu Q; Xu N; Qian KL; Qi JH; Sun YC; Xiao L; Shi XF
Biochem Biophys Res Commun; 2011 Jun; 409(3):448-53. PubMed ID: 21600192
[TBL] [Abstract][Full Text] [Related]
17. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
[TBL] [Abstract][Full Text] [Related]
18. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
Grouix B; Sarra-Bournet F; Leduc M; Simard JC; Hince K; Geerts L; Blais A; Gervais L; Laverdure A; Felton A; Richard J; Ouboudinar J; Gagnon W; Leblond FA; Laurin P; Gagnon L
J Pharmacol Exp Ther; 2018 Oct; 367(1):71-81. PubMed ID: 30093459
[TBL] [Abstract][Full Text] [Related]
19. TRAIL regulates collagen production through HSF1-dependent Hsp47 expression in activated hepatic stellate cells.
Park SJ; Sohn HY; Park SI
Cell Signal; 2013 Jul; 25(7):1635-43. PubMed ID: 23587601
[TBL] [Abstract][Full Text] [Related]
20. The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor.
van Dijk F; Teekamp N; Post E; Schuppan D; Kim YO; Zuidema J; Steendam R; Klose MHM; Meier-Menches SM; Casini A; Horvatovich PL; Sijbrandi NJ; Frijlink HW; Hinrichs WLJ; Poelstra K; Beljaars L; Olinga P
J Control Release; 2019 Feb; 296():250-257. PubMed ID: 30682444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
